1. Home
  2. Publications/Reports
  3. Presentations

Presentations

2023

ASH 2023

- Oral presentation: 

  • D. Wong et al., Cell free MYC DNA copy number identifies high-risk smoldering myeloma and newly diagnosed multiple myeloma. 

- Poster presentations: 

  • K JC Lim et al., Impact of 1q21 gain and amplification on daratumumab-treated multiple myeloma: Real-world data from the Australia-new Zealand and asia-pacific myeloma registries
  • A SO Tang et al., A prospective, multinational study of clinical and biological factors associated with short overall survival in multiple myeloma

Blood 2023

- Annual Breakfast Meeting: 

  • A. Spencer, Latest data and progress from the Australian & New Zeland MRDR. 
  • E. Moore, More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures. 
  • A. Irving, Epidemiological Modelling of Australian Patients with Myeloma (EpiMAP Myeloma).
  • L. Oliver, Asia-Pacific Myeloma & Related Diseases Registry Progress and Results. 

- Poster Presentations: 

  • E. Moore et al., More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient reported outcome measures. 
  • C Wellard et al., Factors associated with self-reported quality of life in a longitudinal study of patients with multiple myeloma (MM) in the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
  • A. Irving et al., Modelling multiple myeloma using best clinical response to treatment to predict overall survival.
  • K JC Lim et al., Inferior outcomes in t(11;14) multiple myeloma: a report from the Australian Lymphoma Leukaemia Group (ALLG) and the ANZ Myeloma and Related Diseases Registry (MRDR).

IMS 2023

- Poster Presentations: 

  • A. Irving et al., Modelling multiple myeloma using best clinical response to treatment to predict overall survival.
  • E. Moore et al., More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient reported outcome measures. 

2022

Australian Society for Medical Research, National Scientific Conference, Nov 2022, Sydney

- Oral Presentation:

  • M Cantley et al., CTX-1 as a blood-based biomarker to identify risk of progression from smouldering myeloma to multiple myeloma.

National Myeloma Worshop, Oct 2022, Yarra Valley

- Oral Presentations:

  • S Lim et al., MRDR and AMaRC trials update.
  • K Bergin et al., Australian data from the Myeloma and Related Disease Registry. 

- Poster Presentations:

  • J Tan et al., Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study.
  • J Ng et al., Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and related diseases registries. 

Blood 2022, September, Sydney, Australia

- MRDR Annual Investigator and Interest Group breakfast meeting:

  • A. Spencer, Myeloma in ANZ: MRDR progress and results
  • T. Van Tonder, More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: introduction to the MY-PROMPT-2 trial
  • J.Ng, Real-world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the ANZ, and the APAC MRDR)
  • A. Spencer, Asia-Pacific MRDR: progress and results

- Oral Presentations:

  • M. Cantley et al., CTX-1 levels can predict individuals at high risk of progression from smouldering myeloma to multiple myeloma
  • S. Lim et al., Continuing poor outlook for relapsed Australian Multiple Myeloma (MM) patients: Impact of limited available therapies

- Poster Presentations:

  • K. Chai et al., Infection patterns and outcomes in patients with newly diagnosed multiple myeloma: Preliminary results from the IMPROVE (Immunoglobulins in myeloma patients: research into outcomes, variation in practice and epidemiology) Cohort Study
  • K. Chai et al., Variation in use of immunoglobulin and impact on survival in multiple myeloma: A report from the Australia/New Zealand MRDR and Asia-Pacific MRDR
  • A. Irving et al., Epidemiological Modelling of Australian Patients with Myeloma, EpiMAP Myeloma
  • J. Tan et al., Validation of the second revision of the International Staging System in a real-world myeloma population (R2-ISS): A Myeloma and Related Diseases Registry (MRDR) Study
  • J. Ng. et al., Real-world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and the Asia-Pacific Myeloma and Related Diseases Registries

International Myeloma Society Meeting 2022, August, Los Angeles, United States

- Poster Presentations:

  • J. Ng. et al., Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and related diseases registries.
  • J. Tan et al., Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study.

EHA Congress 2022, June, Vienna (hybrid)

- Poster presentations:

  • K Chai et al., Variation in use of immunoglobulin and impact on survival in multiple myeloma: A report from the Australia/New Zealand MRDR and Asia-Pacific MRDR (e-Poster)

The European Society for Blood and Marrow Transplantation (EBMT) Meeting 2022, March, (Virtual)

- Poster Presentation:

  • A. Tedjaseputra et al., Long-term follow-up of tandem autologous plus non-myeloablative allogeneic transplant in relapsed myeloma: An Australian report from the Alfred & the Myeloma and Related Diseases Registry (MRDR)

2021

ISOQOL 28th Annual Conference, October (virtual)

- Oral Presentation:

  • E Moore: EQ-5D-5L utility scores at diagnosis and association with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) 

MRDR Annual Investigator and Interest Group Meeting (live webinar)

- Oral Presentations:

  • Andrew Spencer, Real world myeloma in ANZ: registry progress and results
  • P Joy Ho, Impact of biomarker (SLiM) inclusion to MM diagnostic criteria: diagnosis with SLiM alone versus end organ damage (CRAB) in the ANZ MRDR
  • Khai Li Chai, Variation in use of Immunoglobulin in patients with myeloma
  • Kate Vandyke, C-terminal telopeptide 1 (CTX-1) as a marker of high risk for progressing from smouldering to active myeloma 
  • Naomi Aoki, Asia-Pacific MRDR: progress and results

Blood 2021, (virtual conference)

- Oral Presentation

  • PJ Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcome from the ANZ MRDR

- Poster Presentations

  • A Tedjaseputra, Tandem autologous-allogeneic-SCT in relapsed multiple myeloma: a joint report from the Alfred and Myeloma and Related Diseases Registry (MRDR)
  • R Cao, Causes of death in multiple myeloma in Australia: results from the Australian and New Zealand Myeloma and Related Diseases Registry (Narrated poster)
  • E Moore, Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) (Narrated poster)

International Myeloma Workshop, September (hybrid conference, Vienna-based)

- Poster Presentations:

  • PJ Ho, The impact of SLiM criteria in myeloma in a real-life population: clinical characteristics, treatment and outcome from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) (Narrated poster)
  • A Tedjaseputra, Tandem autologous + non-myeloablative allogeneic stem cell transplantation in relapsed multiple myeloma: an Australian joint report from the Alfred and Myeloma and Related Diseases Registry (MRDR)

Nursing Symposium, IMW

- Oral Presentation:

  • E Moore, Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR)

Using PROMs ‘Down-under’ – Supported by ISOQOL, July (virtual Sydney-based conference)

- Oral Presentation:

Monash SPHPM Registry Meeting

- Oral Presentation:

  • A Irving, EpiMAP Myeloma

2020

ASH 2020 (virtual)

- Poster Presentation:

- Abstract:

MRDR Annual Interest Group Meeting (held by webinar, during the 3rd NMW, Australia 2020)

  • A. Spencer, Myeloma in ANZ: MRDR progress and results
  • C. Forsyth, Registry participation in a rural/regional setting
  • D. Petrie, Epidemiological Modelling to deliver better care for Australians with MM
  • K. Huynh, Asia Pacific MRDR: progress and results
  • A. Spencer, AMARC: early phase clinical trials in multiple myeloma

3rd National Myeloma Workshop, Australia 2020 (virtual)

- Oral Presentation:

  • A. Spencer, Early disease progression identifies an ultra-high risk sub-group of newly diagnosed multiple myeloma – A report from the MRDR

- Poster Presentation:

  • J. Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcome from the ANZ MRDR
  • R. Cao, Infection is a major contributor to causes of death in multiple myeloma: results from the ANZ MRDR
  • N. Khajornjiraphan, Outcomes of bortezomib vs lenalidomide in patients with NDMM ineligible for ASCT – initial results from the ANZ MRDR
  • A. Jackson, Outcome of patients with multiple cytogenetic abnormalities at diagnosis: Results from the ANZ  MRDR 

Monash SPHPM Registry Meeting 2020

- Oral Presentation:

  • E. Moore/K Huynh, The Myeloma and Related Diseases Registry (MRDR) and the Asia Pacific arm of the MRDR (APAC MRDR) - an overview (invited)

Haematology Society of Taiwan Meeting 2020

- Oral Presentation:

  • H. Quach, The Australian experience of patients with RRMM (MRDR data used) (invited)

European Haematology Association Congress 2020 (virtual)

- Poster Presentation:

2019

ASH, Orlando, USA, December

- Oral Presentations:

Blood, October, Perth, Australia

- Oral Presentations:

  • A. Spencer et al. MRDR Interest Group breakfast meeting
  • J. Zhao et al., Real-world treatment patterns in relapsed/refractory multiple myeloma in Australia: results from the Myeloma and Related Diseases Registry.
  • E. Moore et al., Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomised controlled trial.
  • H. Blacklock et al., Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry.

International Myeloma Workshop 2019, September, Boston, USA

- Poster Presentations:

  • H. Blacklock et al., Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
  • P. Mollee et al., Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction
  • E. Moore et al., Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomised controlled trial

Alfred Week, June 2019

Myeloma UK Patient Registry Stakeholder Workshop, London, April

  • E. Moore et al., Data with impact

2018

Inaugural Clinical Registries Summit, SPHPM, Monash, November

  • A. Spencer. The Myeloma and Related Diseases Registry
  • N. Aoki, E. Moore. The APAC MRDR and other MRDR International Collaborations

Blood, October, Brisbane

2nd National Myeloma Workshop, Yarra Valley, Australia, September

- Poster Presentations:

3rd Annual Educational Seminar, Myeloma Special Practice Network, HSANZ Nurses Group, Royal Adelaide Hospital: August

  • A. Spencer. Real world outcomes from the Myeloma and Related Diseases Registry.

Registry Special Interest Group meeting, SPHPM, Monash: July

  • E. Moore. News from the Myeloma and Related Diseases Registry.

Quality of Life Office meeting, University of Sydney, July

  • E. Moore and T. King, Growth and outcomes of the Myeloma and Related Diseases Registry.

Alfred week, The Alfred Hospital, June

- Poster presentation:

EBMT, Lisbon, March

- Poster presentation:

2017

HAA, November, Sydney

- Oral presentations:

  • A. Spencer et al., MRDR Interest Group meeting
  • J. Ho, Renal impairment in myeloma: patient & disease characteristics, treatment, stem cell transplant & outcomes from the ANZ MRDR

- Poster Presentations:

European Haematology Association Congress, June 

- Poster presentation:

Victorian Integrated Cancer Services Conference, Melbourne, May

- Oral presentation:

  • A. Spencer, The myeloma and related diseases registry: a tool for practice improvement

Medical scientific advisory group (MSAG) meeting, Melbourne, May 

- Oral presentation:

  • A. Kalff, Myeloma Australia

International Myeloma Workshop, New Delhi, February

- Poster presentations:

Talks including reference to or introduction of the MRDR:

  • H. Blacklock/T. King, National Haematology Nurses meeting, September 2017

2016

Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November 

  • E. Wood

HAA, Melbourne, November

- Oral presentations:

  • A. Spencer et al., MRDR Interest Group meeting
  • K. Bergin et al. Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
  • E. Moore et al. Renal impairment in myeloma: Characteristics and outcomes in patients with and without renal impairment in the ANZ Myeloma and Related Diseases Registry

National Myeloma Workshop, Yarra Valley, Vic, September 2016

- Oral presentation:

  • Z. McQuilten, Putting the pieces together – Epidemiology Practice and Outcomes in Australia and New Zealand

- Poster presentations:

HSANZ Nurses Group, Myeloma Special Practice Network Education Seminar, August

  • E. Moore, MRDR: Maturing data

Monash SPHPM Registry SIG, June

  • E. Moore, MRDR: sustaining growth

ALLG Scientific Meeting, May 

  • A. Spencer, MRDR presentation to ALLG

Myeloma Awareness Day Meeting, Sydney, May

  • B. Rosengarten

Talks including reference to or introduction of the MRDR:

  • S. Gibbs, Myeloma lectures, Royal Darwin Hospital, Aug 2016

2015

Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November 

  • E. Wood

Korean Society of Hematology annual meeting, Seoul, November 

  • A. Spencer

HAA, Adelaide October

- Poster presentation:

MRDR Interest Group meeting

  • A. Spencer

International Myeloma Workshop, Rome, September 2015

- Poster presentation:

Talks including reference to or introduction of the MRDR:

  • A. Kalff, Binding site Educational Workshop, Melbourne, November, 2015
  • A. Kalff, Myeloma Australia, Medical scientific advisory group (MSAG) meeting, Melbourne, November, 2015
  • T. King, Update from IMW 2015 Rome: Nursing Symposium. HSANZ NG NSW Dinner Meeting. Sydney, November 2015 (Poster)
  • T. King, Best practice in the administration of chemotherapy: Bortezomib focus. Tata Memorial Hspt Mumbai; Cancer Institute Chennai; Apollo Hospital Chennai; All India Institute of Medical Sciences (AIMS) Delhi; Rajiv Gandhi Cancer Institute Delhi India, August, 2015
  • A. Kalff, Myeloma Australia, medical scientific advisory group (MSAG) meeting, Melbourne, May, 2015

2014

Myeloma Scientific Advisory Group, Myeloma Foundation Australia, Melbourne, Victoria

  • A. Spencer

MRDR Interest Group Meeting, HAA, Perth, Western Australia, October 

  • A. Spencer

Talks including reference to or introduction of the MRDR:

  • T. King, The Clinical Care of Multiple Myeloma Patients with Targeted Therapy. Taipei, Taiwan, November 2014
  • T. King, The Clinical Care of Multiple Myeloma Patients with Targeted Therapy. Kaohsiung, Taiwan, November 2014
  • T. King, Making sense of myeloma: An overview of treatment. Leukaemia and Blood Cancer Foundation & HSANZ Nurses Group Educational meeting for nurses, September 2014 
  • T. King, Myeloma: An overview of disease, treatments and management of side effects. Leukaemia and Blood Cancer Foundation Patient and Family Forum Auckland New Zealand, September 2014
  • T. King, The Clinical Care of Multiple Myeloma Patients. The First Affiliated Hospital of College of Medicine Zhejiiang University. Hangzhou, China, February 2014
  • T. King, The Clinical Care of Multiple Myeloma Patients. Shanghai Changzheng, Shanghaim, China, February 2014
  • T. King, The Clinical Care of Multiple Myeloma Patients. Institute of Haematology and Blood Diseases Hospital Chinese Academy of Medical Sciences. Tianjin, China, February 2014

2013

HAA Investigator Meeting, Gold Coast, Queensland

  • A. Spencer